Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Due to the complexity of the tumor microenvironment (TME), the conventional drug delivery system fails to deliver the chemotherapeutics in effective concentration for cancer cell kill and is associated with debilitating side effects. Compared with traditional delivery systems, nanoparticles with unique physical properties and elaborate design can efficiently penetrate TME and specifically deliver to the major components in TME. Nanomedicines can deliver immune cargo and promote a stronger immune response and has higher specificity and efficacy. Nanotechnology-based systems can be designed to deliver their content in a spatiotemporally controlled manner in response to tumor internal stimuli, including pH, redox, enzymes, and external stimuli. Therapeutic strategies include inhibiting angiogenesis, remodeling the matrix, modulating immune responses, etc.
Fig.1 Schematic illustration of nanotechnology-based systems. (Mendes, 2021)
One of the strategies used to improve intratumoral drug delivery with nanoparticles is the modification of ECM components. Recent studies, along with clinical trials, have shown that ECM-degrading enzymes, such as collagenase or hyaluronidase, can improve nanoparticle penetration into solid tumors.
Several nanotechnology-mediated strategies have been developed to focus on CAFs-based therapies. For example, the disruption of CAFs can directly cut the links between tumor cells and CAFs. Reprogramming of CAFs to an inactive state or reprogramming of CAFs' phenotype also represents a promising alternative approach.
Recent many attempts remodel the tumor immune microenvironment using novel nanoparticles. Nanoparticle-based approaches can modulate tumor cells and immune cells, such as dendritic cells, T cells, and tumor-associated macrophages.
Nanomedicines can target angiogenesis directly or indirectly, increasing therapeutic efficacy and meanwhile reducing systemic toxicity. These drugs could lead to the destruction of the tumor neovasculature as well as surrounding carcinoma cells, block neovascularization, or promote tumor vasculature normalization.
Overcoming hypoxia is an important strategy in the treatment of solid cancers. Studies have sought to develop functional molecules and nanomaterials including anti-hypoxia agents, hypoxia-active nanoparticles, and hypoxia-targeting agents. The goal is to reverse hypoxia by producing O2, activate the nanoparticles or agents in the hypoxic TME, and target biomarkers of tumor hypoxia to improve the efficacy of the drugs that are administered.
Fig.2 Different strategies are used to target the TME through various kinds of nanomedicines. (Gao, 2019)
The use of nanoparticles in cancer therapy areas becomes a promising approach in recent years. Creative Biolabs has established an advanced platform to manufacture and produce customizable nanoparticles. Our Nanoparticle Tiny Tech can be used to program T cells to create effective CAR-T cells in vitro and in vivo. If you are interested in our services, please feel free to contact us.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
